Hyperhomocysteinaemia and vascular disease - A role for DNA hypomethylation?

Lancet

Volumn 361, Issue 9370, 2003, Pages 1668-1669

  Van Guldener, Coen ^a,b   Stehouwer, Coen D A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ADENOSYLHOMOCYSTEINASE; HOMOCYSTEINE; M FOLIC ACID; METHIONINE; METHYL GROUP; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DNA METHYLATION; FOLIC ACID DEFICIENCY; GENE EXPRESSION; GENOME IMPRINTING; GENOMICS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOCYTE; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STROKE; VASCULAR DISEASE;

EID: 0037986773     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13380-6     Document Type: Note

References (12)

1. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 288:2002;2015-2022.
2. van Guldener C., Stam F., Stehouwer C.D. Homocysteine metabolism in renal failure. Kidney Int. 59:(suppl 78):2001;S234-S237.
3. Baigent C., Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 356:2000;147-152.
4. Mallamaci F., Zoccali C., Tripepi G., et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 61:2002;609-614.
5. van Guldener C., Kulik W., Berger R., et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int. 56:1999;1064-1071.
6. Loehrer F.M., Angst C.P., Brunner F.P., Haefeli W.E., Fowler B. Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions? Nephrol Dial Transplant. 13:1998;656-661.
7. Perna A.F., Ingrosso D., De Santo N.G., Galletti P., Zappia V. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int. 47:1995;247-253.
8. Laukkanen M.O., Mannermaa S., Hiltunen M.O., et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol. 19:1999;2171-2178.
9. Hiltunen M.O., Turunen M.P., Hakkinen T.P., et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 7:2002;5-11.
10. Chen Z., Karaplis A.C., Ackerman S.L., et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet. 10:2001;433-443.
11. Wang H., Yoshizumi M., Lai K., et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem. 272:1997;25380-25385.
12. Perna A.F., Ingrosso D., Zappia V., Galletti P., Capasso G., De Santo N.G. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure: evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest. 91:1993;2497-2503.